succinobucol has been researched along with tranilast in 2 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (tranilast) | Trials (tranilast) | Recent Studies (post-2010) (tranilast) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 583 | 28 | 197 |
| Protein | Taxonomy | succinobucol (IC50) | tranilast (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grégoire, J; L'Allier, PL; Lavoie, MA; Tardif, JC | 1 |
| Douglas, JS | 1 |
2 review(s) available for succinobucol and tranilast
| Article | Year |
|---|---|
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; ortho-Aminobenzoates; Oxidative Stress; Probucol; Sirolimus; Vitamins | 2003 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |